^
    Back
    Association details:
    Biomarker:AGK-BRAF fusion
    Cancer:Melanoma
    Drug:plixorafenib (FORE-8394) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    ASCO 2023
    Title:

    Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.

    Published date:
    05/25/2023
    Excerpt:
    CONTRADICTING EVIDENCE: Of pts with BRAF-fusions, a pt with AGK-BRAF-fused melanoma had CR (DoR 51.8+ months); 46% (6/13) had SD….As single agent anticancer therapy, FORE8394 had antitumor activity in various tumors with BRAF alterations, including pts previously treated with MAPKi and pts with BRAF fusions.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3006
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cell Rep
    Title:

    Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses

    Excerpt:
    Heterogeneous patterns of drug response to RAF and MEK inhibitors of cell lines harboring BRAF fusions compared toBRAFV600E mutant lines...Cell lines with BRAF fusions, except SK-MEL-23, demonstrated resistance to PLX8394, a BRAF inhibitor developed as a “paradox breaker...
    DOI:
    10.1016/j.celrep.2019.09.009